Axl and Met share overlapping downstream pathways with EGFR, and may trigger PI3K/Akt, MAPK/ERK, or NF-κB signaling to promote resistance to TKIs treatment in EGFR-mutant NSCLC [15, 16, 41]. Here, AXL is linked to non-small cell lung carcinoma.